Literature DB >> 23379364

A naturally occurring single amino acid substitution in human TRIM5α linker region affects its anti-HIV type 1 activity and susceptibility to HIV type 1 infection.

Emi E Nakayama1, Toshiaki Nakajima, Gurvinder Kaur, Jun-ich Mimaya, Hiroshi Terunuma, Narinder Mehra, Akinori Kimura, Tatsuo Shioda.   

Abstract

TRIM5α is a factor contributing to intracellular defense mechanisms against retrovirus infection. Rhesus and cynomolgus monkey TRIM5αs potently restrict HIV-1, whereas human TRIM5α shows weak effects against HIV-1. We investigated the association between a single nucleotide polymorphism in the TRIM5α linker 2 region (rs11038628), which substituted aspartic acid (D) for glycine (G) at position 249, with susceptibility to HIV-1 infection in Japanese and Indian subjects. rs11038628 is rare in Europeans but common in Asians and Africans. Functional analyses were performed by multiple-round replication and single-round assays, and indicated that the G249D substitution attenuated anti-HIV-1 activity of human TRIM5α. A slight attenuation of anti-HIV-2 activity was also observed in TRIM5α with 249D. The predicted secondary structure of the linker region suggested that the 249D substitution extended the α-helix in the neighboring coiled-coil domain, suggesting that human TRIM5α with 249D may lose the flexibility required for optimal recognition of retroviral capsid protein. We further analyzed the frequency of G249D in Japanese (93 HIV-1-infected subjects and 279 controls) and Indians (227 HIV-1-infected subjects and 280 controls). The frequency of 249D was significantly higher among HIV-1-infected Indian subjects than in ethnicity-matched control subjects [odds ratio (OR)=1.52, p=0.026]. A similar weak tendency was observed in Japanese subjects, but it was not statistically significant (OR=1.19, p=0.302). In conclusion, G249D, a common variant of human TRIM5α in Asians and Africans, is associated with increased susceptibility to HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23379364      PMCID: PMC3696946          DOI: 10.1089/AID.2012.0369

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  33 in total

1.  Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor.

Authors:  Matthew Stremlau; Michel Perron; Mark Lee; Yuan Li; Byeongwoon Song; Hassan Javanbakht; Felipe Diaz-Griffero; Donovan J Anderson; Wesley I Sundquist; Joseph Sodroski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-15       Impact factor: 11.205

2.  Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection.

Authors:  Hassan Javanbakht; Ping An; Bert Gold; Desiree C Petersen; Colm O'Huigin; George W Nelson; Stephen J O'Brien; Gregory D Kirk; Roger Detels; Susan Buchbinder; Sharyne Donfield; Sergey Shulenin; Byeongwoon Song; Michel J Perron; Matthew Stremlau; Joseph Sodroski; Michael Dean; Cheryl Winkler
Journal:  Virology       Date:  2006-08-02       Impact factor: 3.616

3.  Wild type and H43Y variant of human TRIM5alpha show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro.

Authors:  Emi E Nakayama; Wassila Carpentier; Dominique Costagliola; Tatsuo Shioda; Aikichi Iwamoto; Patrice Debre; Kazuhisa Yoshimura; Brigitte Autran; Shuzo Matsushita; Ioannis Theodorou
Journal:  Immunogenetics       Date:  2007-04-04       Impact factor: 2.846

Review 4.  Human genetic polymorphisms affecting HIV-1 diseases.

Authors:  Tatsuo Shioda; Emi E Nakayama
Journal:  Int J Hematol       Date:  2006-07       Impact factor: 2.490

5.  Copy number variations of CCL3L1 and long-term prognosis of HIV-1 infection in asymptomatic HIV-infected Japanese with hemophilia.

Authors:  Toshiaki Nakajima; Hitoshi Ohtani; Taeko Naruse; Hiroki Shibata; Jun-Ich Mimaya; Hiroshi Terunuma; Akinori Kimura
Journal:  Immunogenetics       Date:  2007-09-14       Impact factor: 2.846

6.  A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas.

Authors:  Haihan Song; Emi E Nakayama; Masaru Yokoyama; Hironori Sato; Jay A Levy; Tatsuo Shioda
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

7.  Comparison of anti-viral activity of rhesus monkey and cynomolgus monkey TRIM5alphas against human immunodeficiency virus type 2 infection.

Authors:  Ken Kono; Haihan Song; Yasuhiro Shingai; Tatsuo Shioda; Emi E Nakayama
Journal:  Virology       Date:  2008-02-21       Impact factor: 3.616

8.  Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.

Authors:  Emily C Speelmon; Devon Livingston-Rosanoff; Shuying Sue Li; Quyen Vu; John Bui; Daniel E Geraghty; Lue Ping Zhao; M Juliana McElrath
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

9.  Role of common human TRIM5alpha variants in HIV-1 disease progression.

Authors:  Valérie Goldschmidt; Gabriela Bleiber; Margaret May; Raquel Martinez; Millàn Ortiz; Amalio Telenti
Journal:  Retrovirology       Date:  2006-08-22       Impact factor: 4.602

10.  The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection.

Authors:  Daniëlle van Manen; Maarten A N Rits; Corrine Beugeling; Karel van Dort; Hanneke Schuitemaker; Neeltje A Kootstra
Journal:  PLoS Pathog       Date:  2008-02-08       Impact factor: 6.823

View more
  9 in total

1.  Genetic polymorphisms of Trim5a are associated with disease progression in acutely and chronically HIV-infected patients.

Authors:  Xin Sun; Wei Li; Wenzhen Liu; Rui Wang; Qunhui Li; Hao Wu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  APOBEC3H polymorphisms and susceptibility to HIV-1 infection in an Indian population.

Authors:  Taeko K Naruse; Daisuke Sakurai; Hitoshi Ohtani; Gaurav Sharma; Surendra K Sharma; Madhu Vajpayee; Narinder K Mehra; Gurvinder Kaur; Akinori Kimura
Journal:  J Hum Genet       Date:  2015-11-12       Impact factor: 3.172

3.  p21(WAF1/CIP1) RNA expression in highly HIV-1 exposed, uninfected individuals.

Authors:  Joshua Herbeck; Suvankar Ghorai; Lennie Chen; Charles R Rinaldo; Joseph B Margolick; Roger Detels; Lisa Jacobson; Steven Wolinsky; James I Mullins
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

Review 4.  Impact of TRIM5α in vivo.

Authors:  Emi E Nakayama; Tatsuo Shioda
Journal:  AIDS       Date:  2015-09-10       Impact factor: 4.177

5.  Previously Unidentified Single Nucleotide Polymorphisms in HIV/AIDS Cases Associate with Clinical Parameters and Disease Progression.

Authors:  Vladimir V Anokhin; Liliia B Bakhteeva; Gulshat R Khasanova; Svetlana F Khaiboullina; Ekaterina V Martynova; Richard L Tillett; Karen A Schlauch; Vincent C Lombardi; Albert A Rizvanov
Journal:  Biomed Res Int       Date:  2016-12-05       Impact factor: 3.411

6.  TRIM5α SPRY/coiled-coil interactions optimize avid retroviral capsid recognition.

Authors:  Marcin D Roganowicz; Sevnur Komurlu; Santanu Mukherjee; Jacek Plewka; Steven L Alam; Katarzyna A Skorupka; Yueping Wan; Damian Dawidowski; David S Cafiso; Barbie K Ganser-Pornillos; Edward M Campbell; Owen Pornillos
Journal:  PLoS Pathog       Date:  2017-10-17       Impact factor: 6.823

7.  Defects in assembly explain reduced antiviral activity of the G249D polymorphism in human TRIM5α.

Authors:  Sevnur Kömürlü; Margret Bradley; Nikolai Smolin; Sabrina Imam; Raymond F Pauszek; Seth L Robia; David Millar; Emi E Nakayama; Tatsuo Shioda; Edward M Campbell
Journal:  PLoS One       Date:  2019-03-19       Impact factor: 3.240

Review 8.  Genomic architecture of HIV-1 infection: current status & challenges.

Authors:  Gurvinder Kaur; Gaurav Sharma; Neeraj Kumar; Mrinali H Kaul; Rhea A Bansal; Madhu Vajpayee; Naveet Wig; Surender K Sharma; Narinder K Mehra
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375

9.  Targeting TRIM5α in HIV Cure Strategies for the CRISPR-Cas9 Era.

Authors:  Daryl Anne Victoria Weatherley; Michael Terence Boswell; Sarah L Rowland-Jones
Journal:  Front Immunol       Date:  2017-11-22       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.